BioCardia Inc.

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brands. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2023

Earnings data Q2 2023

BioCardia, Inc. (NASDAQ:BCDA ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Kumaraguru Raja - Roth Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.

BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript

SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2022 and filed its annual report on Form 10-K for the year ended December 31, 2022 with the Securities and Exchange Commission. The Company will also hold an update conference call at 4:30 PM ET today in which it will discuss business highlights with call details below.

BioCardia Reports Fourth Quarter and Full Year 2022 Business Highlights and Financial Results

SUNNYVALE, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the year ended December 31, 2022 and provide a corporate update conference call on Wednesday, March 29, 2023 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.

BioCardia to Host 2022 Financial Results and Corporate Update Conference Call on March 29, 2023

New Data from Roll-in Cohort of Trial Shows Progression of Patients from Baseline through One and Two Years

Positive Echocardiography Data from BioCardia Phase III CardiAMP Cell Therapy Heart Failure Trial Presented at American College of Cardiology Annual Meeting

SUNNYVALE, Calif. and MULHOUSE, France, Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair ischemic tissues, today announce an amendment to their Clinical Research Supply and Support Agreement.

BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

SUNNYVALE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (Nasdaq: BCDA), a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases issued the following letter to shareholders:

BioCardia Letter to Shareholders

SUNNYVALE, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a Securities Purchase and Registration Rights Agreement (the “Purchase Agreement”) relating to a private placement with certain new and existing qualified institutional buyers, institutional accredited investors and certain directors and officers of the Company (the "Investors"). Pursuant to the Purchase Agreement, the Company agreed to sell to the Investors an aggregate 2,122,017 shares of the Company's common stock at an offering price of $1.68 per share, the average of the closing share prices for the preceding five trading days.

BioCardia Announces $3.6 Million Private Placement of Common Stock

SUNNYVALE, Calif.--( BUSINESS WIRE )--BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration (FDA) approval of its Investigational New Drug (IND) application to initiate a first-in-human Phase I/II clinical trial of its Neurokinin-1 receptor positive (NK1R+) allogeneic human mesenchymal stem cell (MSC) therapy for the treatment of patients with ischemic heart failure.

BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

BioCardia, Inc. (NASDAQ:BCDA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Jules Abraham - CORE IR Peter Altman - President & CEO David McClung - CFO Conference Call Participants Joe Pantginis - H.C. Wainwright Michael Okunewitch - Maxim James Molloy - Alliance Global Partners Operator Good day, and welcome to the BioCardia 2022 Third Quarter Conference Call.

BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 26.09% and 6%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) Reports Q3 Loss, Tops Revenue Estimates

SUNNYVALE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the third quarter of 2022 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2022 with the United States Securities and Exchange Commission (SEC). The Company will also hold an update conference call today at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.

BioCardia Reports Third Quarter 2022 Business Highlights and Financial Results

BioCardia, Inc. (BCDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BioCardia, Inc. (BCDA) Upgraded to Buy: Here's What You Should Know

SUNNYVALE, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and nine months ended September 30, 2022 and provide a corporate update by conference call on Wednesday, November 9, 2022 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.

BioCardia to Host Q3 2022 Financial Results and Corporate Update Conference Call on November 9, 2022

Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time

BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting

Clinical Leadership and Management Call to Follow Clinical Leadership and Management Call to Follow

CardiAMP Cell Therapy Heart Failure Trial Two Year Roll-In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting

SUNNYVALE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ, BCDA), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference.  The conference is being held on September 12-14, 2022. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand.

BioCardia Announces Participation at H.C. Wainwright Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

SUNNYVALE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced it will participate on a panel as a presenting company at Cantor Fitzgerald's Cell and Genetic Medicines Conference. The conference is being held in person on September 15, 2022, at the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue.

BioCardia to Participate in Cantor Fitzgerald's Cell and Genetic Medicines Conference

Adaptive Statistical Analysis Plan Recommended

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

Here is how BioCardia, Inc. (BCDA) and Ensign Group (ENSG) have performed compared to their sector so far this year.

Has BioCardia (BCDA) Outpaced Other Medical Stocks This Year?

SUNNYVALE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with BlueRock Therapeutics LP for the delivery of BlueRock's cell therapy product candidates for the treatment of heart failure utilizing BioCardia's minimally invasive biotherapeutic delivery product candidates.

BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock's Cell Therapy to Treat Heart Failure

BioCardia, Inc. (NASDAQ:BCDA ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Jules Abraham - IR, CORE IR Peter Altman - President and CEO David McClung - CFO Conference Call Participants Kumaraguru Raja - Brookline Capital Markets Michael Okunewitch - Maxim Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good day and welcome to the BioCardia 2022 Second Quarter Conference Call.

BioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcript

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 50% and 412.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates

SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2022 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2022 with the United States Securities and Exchange Commission (SEC). The Company will also hold an update conference call today at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.

BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results

SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will report its financial results for the three and six months ended June 30, 2022 and provide a corporate update by conference call on Wednesday, August 10, 2022 at 4:30 PM ET. Following management's formal remarks, there will be a question-and-answer session.

BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022

SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP® Cell Therapy Heart Failure Trial.

News for BioCardia Inc. Stock (BCDA)